Eidos Therapeutics, Inc. IPO Research Information

Eidos Therapeutics, Inc. IPO Advisory

Share this IPO Profile:

Smart Search

For IPO Boutique's "scale of 1 to 5" BUY rating on Eidos Therapeutics, Inc., and our comprehensive analysis, click "Buy Market Research".

Company	Symbol	Price Range	Issue Price	Open	Shares	Trade Date
Eidos Therapeutics, Inc.	EIDX - NASDAQ	$15.00-$17.00	$17.00	$20.00	6.3 million	6/20/2018
Underwriter(s): J.P. Morgan, BofA Merrill Lynch
Co-Manager(s): Barclays
Industry: Health Care
Filing(s): Filed 2018-05-25 Terms Added 2018-06-08 Final Prospectus 2018-06-21

Eidos Therapeutics, Inc. Quote & Chart - Click for current quote - EIDX

About Eidos Therapeutics, Inc. (adapted from Eidos Therapeutics, Inc. prospectus):
They are a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin, or TTR, amyloidosis, or ATTR.

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.

IPO Boutique aggregates information on public companies and private companies, such as "EIDX" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.